Anebulo Pharmaceuticals, Inc. (ANEB): R&D Expense
$4.30M
Year ended 2025-06-30
$3.74M
Trailing 12 months to 2025-12-31
+13.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $4.30M | +21.2% | 2025-09-29, From 2024-07-01 |
| 2024-06-30 | $3.55M | -36.6% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $5.60M | +89.1% | 2024-09-25, From 2022-07-01 |
| 2022-06-30 | $2.96M | +30.5% | 2023-09-22, From 2021-07-01 |
| 2021-06-30 | $2.27M | n/a | 2022-09-09, From 2020-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | 2025-06-30 | $4.30M | +21.2% |
| Turn Therapeutics Inc. (TTRX) | 2025-12-31 | $265.6K | +8.0% |
| Imunon, Inc. (IMNN) | 2025-12-31 | $7.78M | -33.2% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $1.14M | -90.3% |
| Nomad Power Solutions, Inc. (NMAD) | 2025-12-31 | $254.9K | -64.9% |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $4.06M | +14.5% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $2.99M | n/a |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $147.0K | +40.5% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $1.13M | +13.5% |
Compare ANEB, TTRX, IMNN, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗